Can you take Dimethyl fumarate with Medinol Under 6?

The acetaminophen in Medinol Under 6 has a major potential interaction with Alcoholism.

Chronic alcohol abusers may be at increased risk of hepatotoxicity during treatment with acetaminophen (APAP). Severe liver injury, including cases of acute liver failure resulting in liver transplant and death, has been reported in patients using acetaminophen. Therapy with acetaminophen should be administered cautiously, if at all, in patients who consume three or more alcoholic drinks a day. In general, patients should avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure. They should also be advised to seek medical attention if they experience signs and symptoms of liver injury such as fever, rash, anorexia, nausea, vomiting, fatigue, right upper quadrant pain, dark urine, and jaundice.

The acetaminophen in Medinol Under 6 has a major potential interaction with Dehydration.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Dimethyl fumarate has a moderate potential interaction with Immunodeficiency.

Progressive multifocal leukoencephalopathy (PML) has occurred in patients with multiple sclerosis (MS) treated with dimethyl fumarate; PML is an opportunistic viral infection of the brain caused by the John Cunningham virus (JC virus) that generally only occurs in immunocompromised patients and usually leads to death or severe disability. Caution and monitoring are advised in patients with MS. Dimethyl fumarate should be withheld at the first sign/symptom suggestive of PML and an appropriate diagnostic evaluation should be performed.

Dimethyl fumarate has a moderate potential interaction with Infection.

The use of dimethyl fumarate may decrease lymphocyte counts. Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients. CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated. Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered. Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.

Dimethyl fumarate has a moderate potential interaction with Infection.

Serious cases of herpes zoster have occurred in patients treated with dimethyl fumarate; patients should be monitored for signs/symptoms of herpes zoster while on dimethyl fumarate. Other serious opportunistic infections have occurred with dimethyl fumarate, including cases of serious viral, fungal, and bacterial infections. Patients with signs/symptoms consistent with any of these infections should undergo prompt diagnostic evaluation and receive appropriate treatment. Withholding dimethyl fumarate treatment in patients with herpes zoster or other serious infections until the infection has resolved should be considered.

The acetaminophen in Medinol Under 6 has a major potential interaction with Liver Disease.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

Dimethyl fumarate has a moderate potential interaction with Liver Disease.

Dimethyl fumarate has not been studied in patients with liver dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients. Clinically significant cases of liver injury have been reported in patients treated with dimethyl fumarate in the postmarketing setting. Signs/symptoms of liver injury, including elevation of serum aminotransferases to greater than 5-fold the upper limit of normal (ULN) and elevation of total bilirubin to greater than 2-fold ULN have been observed; these abnormalities resolved upon treatment discontinuation. Elevations of hepatic transaminases (most no greater than 3 times ULN) were observed during controlled trials. Serum aminotransferase, alkaline phosphatase, and total bilirubin levels should be obtained prior to and during treatment with dimethyl fumarate, as clinically indicated. Therapy should be discontinued if clinically significant liver injury induced by dimethyl fumarate is suspected.

Dimethyl fumarate has a moderate potential interaction with Lymphocytopenia.

The use of dimethyl fumarate may decrease lymphocyte counts. Dimethyl fumarate has not been studied in patients with preexisting low lymphocyte counts; caution is advised in these patients. CBC (including lymphocyte count) should be obtained before initiating treatment with dimethyl fumarate, 6 months after starting treatment, every 6 to 12 months thereafter, and as clinically indicated. Interruption of therapy in patients with lymphocyte counts less than 0.5 x 10(9) cells/L persisting for more than 6 months and withholding treatment from patients with serious infections until resolution should be considered. Caution is recommended and decisions about whether or not to restart dimethyl fumarate should be individualized based on clinical circumstances.

The acetaminophen in Medinol Under 6 has a major potential interaction with Malnourishment.

Acetaminophen is contraindicated in patients with severe hepatic impairment or severe active liver disease. Patients with hepatic impairment may be at increased risk of toxicity. Severe liver injury, including cases of acute liver failure and death, have been reported in patients using this drug. Clinical monitoring of hepatic function is recommended. Caution is advised if using acetaminophen in patients with chronic malnutrition or severe hypovolemia. Instruct patients to avoid drinking alcohol while taking acetaminophen-containing medications. Patients should be warned not to exceed the maximum recommended total daily dosage of acetaminophen (4 g/day in adults and children 12 years of age or older), and to read all prescription and over-the-counter medication labels to ensure they are not taking multiple acetaminophen-containing products, or check with a healthcare professional if they are unsure.

The acetaminophen in Medinol Under 6 has a moderate potential interaction with Phenylketonuria.

Several oral acetaminophen and acetaminophen-combination products, particularly flavored chewable tablets, contain the artificial sweetener, aspartame (NutraSweet). Aspartame is converted to phenylalanine in the gastrointestinal tract following ingestion. Chewable and effervescent formulations of acetaminophen products may also contain phenylalanine. The aspartame/phenylalanine content should be considered when these products are used in patients who must restrict their intake of phenylalanine (i.e. phenylketonurics).

Dimethyl fumarate has a moderate potential interaction with Renal Dysfunction.

Dimethyl fumarate has not been studied in patients with renal dysfunction; although no dosage adjustment is needed, caution is recommended when using dimethyl fumarate in these patients.